Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
Asgard Therapeutics will present preclinical data on its lead gene therapy asset AT-108 at the AACR Annual Meeting 2026, demonstrating its potential in cancer treatment. AT-108 uses in vivo cell reprogramming to induce a personalized anti-tumor immune response.
Asgard Therapeutics, a biotech company based in Lund, Sweden, is set to present preclinical data on its lead gene therapy asset AT-108 at the AACR Annual Meeting 2026 in San Diego, California. AT-108 utilizes in vivo cell reprogramming technology to directly reprogram tumor cells into dendritic cells, inducing a personalized anti-tumor immune response. The presentation will detail preclinical data showing AT-108's systemic, dose-dependent efficacy with broad tumor activity. Asgard is progressing AT-108 toward clinical development, focusing on solid tumors, and is advancing IND-enabling studies and CMC development. The company's technology aims to set in motion efficient and personalized immune responses against cancer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.